Drug discovery

MorphoSys and Heptares explore new targets

Friday 8 March 2013

Interviewee/Contributer: Malcolm Weir

Organisation: Heptares Therapeutics Ltd

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Encode project produces many findings

Monday 15 October 2012

Interviewee/Contributer: Victoria English

Organisation: MedNous

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Epigenetics can transform drug development

Sunday 14 October 2012

Interviewee/Contributer: Bernd Hentsch et al

Organisation: 4SC AG

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Cystic fibrosis: one mutation down, more to come

Friday 14 September 2012

Interviewee/Contributer: Eric Olson

Organisation: Vertex Pharmaceuticals Inc

Full text available to subscribers only. Click here for information on subscribing to MedNous.

How tissue plasminogen activator was discovered

Friday 27 April 2012

Interviewee/Contributer: Désiré Collen

Organisation: ThromboGenics NV

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Risk sharing with Pharma -- is this the way to go?

Tuesday 15 November 2011

Interviewee/Contributer: Onno van de Stolpe

Organisation: Galapagos NV

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Advancing a modular approach to antibody design

Sunday 23 October 2011

Interviewee/Contributer: Kevin FitzGerald

Organisation: F-Star GmbH

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Cellzome secures a lead in drug discovery

Friday 15 July 2011

Interviewee/Contributer: Tim Edwards

Organisation: Cellzome

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Critical Path Initiative at the FDA

Saturday 10 July 2010

Interviewee/Contributer: Leonard Sacks

Organisation: US Food and Drug Administration

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Noxxon Pharma AG: Through the looking glass to new therapies

Wednesday 10 March 2010

Interviewee/Contributer: Sven Klussmann

Organisation: Noxxon Pharma AG

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Syndicate content